-
1 Comment
Voyageur Pharmaceuticals Ltd is currently in a long term uptrend where the price is trading 14.3% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Voyageur Pharmaceuticals Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 34.0% to $-286K since the same quarter in the previous year.
Finally, its free cash flow grew by 31.9% to $-177K since the same quarter in the previous year.
Based on the above factors, Voyageur Pharmaceuticals Ltd gets an overall score of 3/5.
| Exchange | V |
|---|---|
| CurrencyCode | CAD |
| ISIN | CA92918C1014 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Beta | 0.44 |
|---|---|
| Target Price | 0.55 |
| Market Cap | 28M |
| PE Ratio | None |
| Dividend Yield | None |
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in the acquiring, exploring, and developing raw materials for pharmaceutical products in the province of British Columbia, Canada, and the state of Utah. It develops barium, iodine-based APIs, and imaging contrast agents for medical radiology. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. is headquartered in Calgary, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for VM.V using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
